Epigral Q1 FY27 Results: PAT Up 25%, ₹600 Crore Capex Approved for Epoxy Resin Expansion

What Happened ?

key details

₹600 Crore Expansion into Epoxy Resin & Formulations:

Epigral’s Board has approved an estimated ₹600 crore capital expenditure to establish an Epoxy Resin & Formulations plant with an annual production capacity of 1,25,000 TPA. The facility marks the company’s entry into one of the fastest-growing specialty chemical segments and represents a major forward integration initiative. Commercial production is targeted for H2 FY28.

The proposed Epoxy Resin business is aimed at serving industries including:

• Renewable energy, particularly wind turbine blades.
• Construction and infrastructure.
• Electronics and electrical insulation.
• Automotive and transportation.
• Marine and aerospace applications.
• Industrial coatings, adhesives and flooring.
• Semiconductor and other high-performance industrial applications.

Multi-Purpose Plant (MPP) to Expand Specialty Chemicals Portfolio:

Alongside the epoxy project, Epigral will establish a Multi-Purpose Plant (MPP) as part of its downstream integration strategy. The new facility will manufacture products based on the Epichlorohydrin (ECH) and Chlorotoluenes value chains and is also scheduled for commissioning in H2 FY28. 

The MPP is intended to address growing domestic demand for:

• Pharmaceutical intermediates.
• Agrochemical intermediates.
• Water treatment chemicals.
• Other downstream specialty chemical products.

Integrated Manufacturing Provides Cost Advantage:

A key strategic advantage of the expansion is Epigral’s integrated manufacturing complex at Dahej, Gujarat.

More than 50% of the raw material value required for the proposed Epoxy Resin project will be sourced internally through the company’s existing production of:

• Epichlorohydrin (ECH).
• Caustic Soda.

This integrated approach is expected to:

• Improve manufacturing efficiencies.
• Reduce dependence on external suppliers.
• Enhance cost competitiveness.
• Increase value addition across the company’s chemical portfolio.

The company believes this integration strengthens its competitive positioning while supporting long-term margin expansion.

Pilot Plant to Accelerate Commercialisation:

To support commercial-scale production, Epigral is establishing a pilot plant for both the Epoxy Resin & Formulations business and the Multi-Purpose Plant.

The pilot facility is expected to:

• Optimise manufacturing processes.
• Validate product quality.
• Facilitate customer approvals.
• Reduce execution risk before full commercial commissioning.

Existing Capacity Expansion Remains on Track:

Apart from the newly approved projects, Epigral confirmed that several ongoing expansion projects continue to progress according to schedule and within the approved budget.

These include:

• Additional 75 KTPA CPVC Resin capacity.
• Additional 50 KTPA Epichlorohydrin (ECH) capacity.
• Additional 19.80 MW Wind-Solar Hybrid Power Plant.

All three projects are expected to be commissioned during Q2 FY27, strengthening manufacturing capabilities, improving energy efficiency and supporting future downstream growth. 

Portfolio Transition Towards High-Value Specialty Chemicals:

Epigral continues to transform its business mix from conventional chlor-alkali products toward higher-value derivatives and specialty chemicals.

According to the investor presentation:

• Derivatives and specialty chemicals contributed 52% of revenue in FY26.
• The company expects this contribution to increase to approximately 70% by FY28, reducing dependence on commodity chemicals and improving earnings quality.

Its integrated portfolio now spans:

• Chlor-Alkali.
• Chloromethanes.
• Hydrogen Peroxide.
• CPVC Resin.
• Epichlorohydrin (ECH).
• Chlorotoluenes Value Chain.
• Epoxy Resin (planned).
• Multi-Purpose downstream specialty chemicals (planned). 

Note:

• The investor presentation outlines the strategic rationale, capital expenditure, project timelines and manufacturing integration benefits. However, it does not disclose the expected revenue contribution, project IRR, payback period or earnings impact from the proposed Epoxy Resin and Multi-Purpose Plant projects.

Risk Analysis

Summary:

• Epigral delivered strong quarterly performance while advancing multiple strategic expansion projects. However, timely execution of the approved capital expenditure, stable raw material availability and sustained demand for specialty chemicals will be important for realizing the expected long-term benefits. The investor presentation does not provide financial guidance or projected returns from the newly announced projects.  

Key Risks:

• The ₹600 crore Epoxy Resin & Formulations plant and Multi-Purpose Plant are expected to commence commercial operations only in H2 FY28, making project execution and commissioning timelines critical. 
• Raw material price volatility, freight costs and geopolitical developments could continue to influence operating margins and procurement costs. 
• Commercial success of the Epoxy Resin business will depend on customer approvals, product acceptance and ramp-up after pilot validation.
• The investor presentation does not disclose expected revenue contribution, project IRR or payback period for the proposed expansion projects.

Worst Case:

• Delays in commissioning, slower customer adoption or prolonged weakness in specialty chemical demand could postpone the anticipated benefits of the ₹600 crore expansion programme.

Risk Level: Medium

Company Commentary

• Chairman & Managing Director Maulik Patel stated that Epigral delivered resilient performance during the quarter despite geopolitical uncertainty, volatile raw material prices and higher logistics costs, supported by its diversified product portfolio and integrated manufacturing operations. 
• Management said the approved Epoxy Resin & Formulations plant and Multi-Purpose Plant represent the company’s next phase of downstream integration and are expected to create additional value by utilizing internally manufactured Epichlorohydrin and Caustic Soda.
• The company reiterated its focus on expanding the specialty chemicals portfolio while strengthening operational efficiency, improving product mix and delivering sustainable long-term growth through disciplined capital allocation.
• Management also confirmed that the ongoing CPVC Resin, Epichlorohydrin and Wind-Solar Hybrid Power Plant expansion projects remain on schedule and within the approved budget.